Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07167693 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes
A Phase 1 study of Diabetic Ketoacidosis and Diabetes (DM), sponsored by David K Carroll.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07167693 is a Phase 1 study of Diabetic Ketoacidosis and Diabetes (DM) that is actively recruiting participants, run by David K Carroll. The registered enrollment target is 60 participants, above the 43-participant average among 3 other Diabetic Ketoacidosis trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07167693, a Phase 1 study of Diabetic Ketoacidosis and Diabetes (DM), is actively recruiting participants, sponsored by David K Carroll.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Diabetic ketoacidosis (DKA) is increasingly recognized in adults with "ketone-prone" type 2 diabetes. In many of these patients, the pancreas can still make insulin but becomes temporarily "stunned" during severe, prolonged high blood sugar. Arginine is a naturally occurring amino acid that can trigger the pancreas to release its own insulin when glucose is high. It is FDA-approved for other uses and has been given intravenously for decades with a strong safety record. Whether a single arginine infusion given early during DKA can safely boost the body's insulin and speed recovery has not been tested. This randomized, double-blind, placebo-controlled, phase 1/2 trial will enroll 60 adults who present to one of four Detroit-area emergency departments with DKA consistent with ketone-prone type 2 diabetes (high glucose and significant ketones). Participants will receive standard DKA care ordered by their clinicians. In addition, under blinded conditions they will receive either arginine hydrochloride 30 grams (in 300 mL) or placebo (normal saline), infused intravenously over 30 minutes as early as feasible after DKA is recognized. The main question is whether arginine increases endogenous (self-made) insulin soon after infusion. We will measure C-peptide (a marker released in equal amounts with insulin) and glucose at 10, 30, and 90 minutes after the start of the infusion and calculate the C-peptide/glucose ratio. Secondary measures include the rate of ketone (β-hydroxybutyrate) clearance and the total insulin dose required in the first 24 hours. Additional blood tests will examine arginine and related amino acids, and a small sample of platelets will be used to explore mitochondrial function. Safety will be closely monitored during and after the infusion, and participants will be contacted at 90 days to assess for any delayed problems. Potential risks include temporary flushing, nausea, or headache; the infusion can be stopped at any time if needed. Potential benefi
Conditions Studied
Interventions
- DRUG Arginine hydrochloride
- DRUG Sodium Chloride 0.9%
Study Locations (1)
Michigan
- Detroit Medical Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07167693
The ClinicalTrials.gov registry entry for NCT07167693 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 43-participant average among 3 other Diabetic Ketoacidosis trials with a reported enrollment target (40% higher). The listed sponsor is David K Carroll, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetic Ketoacidosis appearing as the primary indexed condition, and to 2 interventions - of which Arginine hydrochloride is the first listed.
NCT07167693 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07167693 about?
NCT07167693 is a clinical study titled "Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes". Diabetic ketoacidosis (DKA) is increasingly recognized in adults with "ketone-prone" type 2 diabetes. In many of these patients, the pancreas can still make insulin but becomes temporarily "stunned" during severe, prolonged high blood sugar. Arginine is a naturally occurring amino acid that can trig...
What is the current status of trial NCT07167693?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-12-19. Estimated completion is 2027-12-31.
What conditions does trial NCT07167693 study?
This clinical trial studies the following conditions: Diabetic Ketoacidosis, Diabetes (DM), Hyperglycaemia (Diabetic), Ketosis Prone Diabetes.
What interventions are being tested in trial NCT07167693?
The interventions under investigation include: Arginine hydrochloride (DRUG), Sodium Chloride 0.9% (DRUG).
Who is sponsoring clinical trial NCT07167693?
This trial is sponsored by David K Carroll, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07167693 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Ketoacidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.